Omeros Corporation Total Assets
Omeros Corporation total assets. Based on the latest financial reports, Omeros Corporation (OMER) holds total assets worth $286.83 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Omeros Corporation for the company's overall valuation and market capitalisation.
Total Assets of Omeros Corporation (2007–2025)
Total assets of Omeros Corporation from 2007 to 2025. This chart illustrates how Omeros Corporation's total assets have evolved over time, based on quarterly financial data. See OMER stock price for real-time trading data and today's change.
Omeros Corporation - Asset Composition Analysis
Omeros Corporation Total Assets Breakdown (December 2025)
Omeros Corporation total assets breakdown as of December 2025. Omeros Corporation's total assets of $286.83 Million consist of 66.2% current assets and 33.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.0% |
| Accounts Receivable | $36.27 Million | 11.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Omeros Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Omeros Corporation working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Omeros Corporation's current assets represent 66.2% of total assets in 2025, a decrease from 90.1% in 2007.
- Cash Position: Cash and equivalents constituted 3.0% of total assets in 2025, down from 21.8% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 11.1% of total assets.
Omeros Corporation Competitors by Total Assets
Key competitors of Omeros Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Omeros Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.95 | 0.81 | 2.13 |
| Quick Ratio | 1.94 | 0.81 | 2.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $90.28 Million | $-15.86 Million | $48.53 Million |
Omeros Corporation - Advanced Valuation Insights
This section examines the relationship between Omeros Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.44 |
| Latest Market Cap to Assets Ratio | 4.06 |
| Asset Growth Rate (YoY) | 17.5% |
| Total Assets | $325.63 Million |
| Market Capitalization | $1.32 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Omeros Corporation's assets at a significant premium (4.06x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Omeros Corporation's assets grew by 17.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Omeros Corporation (2007–2025)
The table below shows the annual total assets of Omeros Corporation from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $325.63 Million | +17.52% |
| 2024-12-31 | $277.08 Million | -26.75% |
| 2023-12-31 | $378.27 Million | -35.99% |
| 2022-12-31 | $590.97 Million | +40.95% |
| 2021-12-31 | $419.27 Million | +131.59% |
| 2020-12-31 | $181.04 Million | +32.18% |
| 2019-12-31 | $136.97 Million | +42.77% |
| 2018-12-31 | $95.94 Million | -17.53% |
| 2017-12-31 | $116.33 Million | +72.91% |
| 2016-12-31 | $67.28 Million | +37.32% |
| 2015-12-31 | $48.99 Million | +341.79% |
| 2014-12-31 | $11.09 Million | -32.93% |
| 2013-12-31 | $16.54 Million | -37.78% |
| 2012-12-31 | $26.57 Million | -1.51% |
| 2011-12-31 | $26.98 Million | -40.96% |
| 2010-12-31 | $45.70 Million | -26.36% |
| 2009-12-31 | $62.06 Million | +186.25% |
| 2008-12-31 | $21.68 Million | -20.18% |
| 2007-12-31 | $27.16 Million | -- |
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinic… Read more